Synergy Research Group (SynRG) has become the first Russian member of the European Forum for Good Clinical Practice (EFGCP). Founded in 1993, EFGCP aims to promote Good Clinical Practice and high-quality biomedical research throughout Europe.
“These goals and objectives are very much in line with our own long-term strategies, so we’d be very pleased to join our efforts with EFGCP,” said Igor Stefanov, SynRG General Manager, in a press release.
From the beginning of its membership, SynRG became involved in EFGCP activities and plans on integrating Russia into European R&D community. In December, an EFGCP Board Meeting endorsed a plan to include Russia in the area of EFGCP influence, and, as a result to establish a trustworthy reputation of Russia as a peer ethical partner among the International Clinical Research Community.
“Being a natural member of European family; de-jure as a formal non-member of EU; and de-facto as a terra incognita for most Europeans, Russia suffers from this triple nature, as a result of ignorance, misinterpretation, and lack of trust and rapport from the European community. We are keen to change this situation,” said Igor Stefanov in that same press release.
For more on the collaboration between SynRG and EFGCP, click here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.